Biotech dominates the top five investment trusts of Q3
By Sonia Rach, 5 Oct 18
Stifel data reveals the top investment trusts during Q3 2018
Lead investment manager, Carl Harald Janson said: “Demographic changes and innovation continued to drive growth in the biotech sector during Q3.
“Income hungry demand, attracted by IBT’s 4% dividend, led to IBT’s discount contracting further over the period. With US dollar denominated investments dominating the portfolio, IBT benefits from a weak sterling, which added to Q3 performance”.
Janson is joined by Marek Poszepczynski, Kate Bingham and Ailsa Craig (pictured) on the trust.
It has underperformed the IT Biotechnology and Healthcare benchmark on a one-year and three-year basis, with returns of 7.5% and 52.4% against 15.6% and 59.8%, according to FE. But, on a five-year basis, it has outperformed with returns of 144.6% versus 134.3%.